Scarica l'app Stockscreener
13.53
2.81%
0.37
Pre-mercato:
13.65
0.12
+0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.16
Aprire:
$13.16
Volume 24 ore:
479.50K
Relative Volume:
0.76
Capitalizzazione di mercato:
$738.70M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-5.7089
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
+4.40%
1M Prestazione:
+14.08%
6M Prestazione:
+31.87%
1 anno Prestazione:
-6.33%
Intervallo 1D:
$13.04
$13.65
Intervallo di 1 settimana:
$12.75
$13.65
Portata 52W:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
13.53 | 718.50M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - uk.finance.yahoo.com
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - MarketScreener
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
Can Stoke Therapeutics Inc. outperform under higher oil pricesStrong Support Zone Stocks - thegnnews.com
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome - Clinical Trials Arena
Stoke Therapeutics Earnings Preview: Analyst Expectations and Market Sentiments - AInvest
A Look Ahead: Stoke Therapeutics's Earnings Forecast - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Ariva
First Dravet syndrome patient dosed in Phase 3 trial of zorevunersen - Investing.com Canada
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Institutional scanner results for Stoke Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
Multi asset correlation models including Stoke Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Can momentum traders help lift Stoke Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Will Stoke Therapeutics Inc. bounce back from current supportLow Drawdown Stock Screener with Analysis - Newser
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEquity Forecast with Predictive AI Screener - Newser
Stoke Therapeutics Inc. Outperforms Peers on Volume MetricsAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Stoke Therapeutics STOK 2025Q2 Earnings Preview Upside Potential on Innovative Fluorescence Applications - AInvest
Stoke Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Stoke Therapeutics to Host Q2 2025 Business and Financial Update Webcast and Conference Call. - AInvest
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - The Globe and Mail
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Stoke Therapeutics to Showcase Dravet Syndrome RNA Treatment at Major Growth Conference - Stock Titan
Published on: 2025-08-05 00:18:53 - beatles.ru
Combining machine learning predictions for Stoke Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Trendline Breach Raises Concern for Stoke Therapeutics Inc. InvestorsVerified Signal From Chart Patterns Detected - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Is Stoke Therapeutics Inc. a growth stock or a value stockRemarkable growth - Jammu Links News
Is it the right time to buy Stoke Therapeutics Inc. stockMaximize returns with expert trading insights - Jammu Links News
How many analysts rate Stoke Therapeutics Inc. as a “Buy”Invest confidently with data-driven strategies - Jammu Links News
What analysts say about Stoke Therapeutics Inc. stockRapid return acceleration - Jammu Links News
Does Stoke Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough results with expert guidance - Jammu Links News
How strong is Stoke Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
How volatile is Stoke Therapeutics Inc. stock compared to the marketUnlock expert insights for smarter investing - Jammu Links News
How does Stoke Therapeutics Inc. compare to its industry peersRapid wealth accumulation - Jammu Links News
What catalysts could drive Stoke Therapeutics Inc. stock higher in 2025Double or triple returns - Jammu Links News
What drives Stoke Therapeutics Inc. stock priceDiscover investment plans that deliver results - Jammu Links News
What makes Stoke Therapeutics Inc. stock price move sharplyUnlock hidden market opportunities today - Jammu Links News
When is Stoke Therapeutics Inc. stock expected to show significant growthGet expert insights on market-moving stocks - Jammu Links News
What are Stoke Therapeutics Inc. company’s key revenue driversExpert Picks Target Finder For Consistent Profits - Jammu Links News
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for - MSN
Real time breakdown of Stoke Therapeutics Inc. stock performanceAI Trading Suggestions With Accuracy Focus Released - metal.it
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):